• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific wants Supreme Court to toss $309m patent loss to ICD pioneer Mirowski

Boston Scientific wants Supreme Court to toss $309m patent loss to ICD pioneer Mirowski

October 19, 2016 By Brad Perriello

Boston ScientificBoston Scientific (NYSE:BSX) asked the U.S. Supreme Court this month to toss a Maryland state court decision over cardiac rhythm management device patents that awarded more than $309 million to the family of the late physician who helped invent the implantable cardioverter defibrillator, Dr. Michel Mirowski.

Marlborough, Mass.-based Boston Scientific lost the judgment in September 2014, part of a long-running patent war with Mirowski Family Ventures. A jury in Maryland’s Montgomery County Circuit Court awarded the damages to the family (Mirowski died in 1990), which originally sued Boston Scientific and its Guidant subsidiary over a secret deal with rival St. Jude Medical (NYSE:STJ). The family alleged that the deal cut Mirowski out of some $570 million in potential royalties and damages. The jury awarded MFV more than $86.5 million in damages “for royalties owed for 2002 and 2003;” another $142.6 million in damages for “the financial harm in the Indiana lawsuit;” and $80.2 million and pre-judgment interest “in connection with the defendants’ settlement with St. Jude,” according to court documents.

In its Oct. 7 petition for certiorari from the Supremes, Boston Scientific argued that the Maryland state court overlooked basic patent law requirements that the high court should review in light of its 2013 decision in another case.

“This court stated in Gunn v. Minton that state courts resolving state-law claims that implicate patent-law questions ‘can be expected to hew closely to the pertinent federal precedents.’ The court below ignored that command,” Boston Scientific wrote in the petition. “It failed to carry out the basic duty of claim construction, instead leaving the jury to determine the scope of the patent’s claims. This failure, in turn, infected both the jury’s verdict as to MFV’s claim for additional royalties and its decision to MFV’s improper settlement claim. And the court disposed of questions of substantive patent law in a manner plainly inconsistent with well-established patent precedents. The egregious departures from federal patent law in the decision below warrant this court’s review.”

The Mirowski family filed suit in February 2013 in the Maryland state court, where the case was litigated until Boston Scientific won its bid to remove the case to federal court in September of that year, according to court documents. In June Judge William Quarles Jr. of the U.S. District Court for Maryland found that Boston Scientific’s removal of the case to the federal court was untimely, according to court documents, remanding the case back to the Maryland state court.

Filed Under: Cardiovascular, Legal News, Patent Infringement Tagged With: Boston Scientific, Cardiac Rhythm Management, U.S. Supreme Court

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy